DNAM-1 Antibody (11A8): sc-53581
- DNAM-1 Antibody (11A8) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against NK cell lines of human origin
- recommended for detection of DNAM-1 of human origin by WB, IP and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for DNAM-1 Antibody (11A8) for WB applications. These reagents are now offered in bundles with DNAM-1 Antibody (11A8) (see ordering information below).
QUICK LINKS
DNAM-1 Antibody (11A8) is a mouse monoclonal IgG1 antibody that detects DNAM-1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). DNAM-1, also known as DNAX accessory molecule-1, is a crucial transmembrane glycoprotein composed of 318 amino acids, featuring two immunoglobulin-like domains that play a significant role in immune responses. DNAM-1 is primarily located on the surface of T cells and natural killer (NK) cells, where DNAM-1 facilitates primary adhesion during cytotoxic T lymphocyte-mediated cytotoxicity. DNAM-1 interaction with ligands is essential for the activation and proliferation of immune cells, thereby enhancing their ability to target and eliminate infected or malignant cells. Proper functioning of DNAM-1 is vital for maintaining effective immune surveillance and response, making DNAM-1 an important focus for research in immunology and cancer therapy. Anti-DNAM-1 antibody (11A8) is an invaluable tool for studying the dynamics of immune cell activation and the mechanisms underlying cytotoxicity in various biological contexts.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
DNAM-1 Antibody (11A8) References:
- Cancer immunotherapy using NKG2D and DNAM-1 systems. | Morisaki, T., et al. 2012. Anticancer Res. 32: 2241-7. PMID: 22641658
- DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. | de Andrade, LF., et al. 2014. Immunol Cell Biol. 92: 237-44. PMID: 24343663
- Coordinated expression of DNAM-1 and LFA-1 in educated NK cells. | Enqvist, M., et al. 2015. J Immunol. 194: 4518-27. PMID: 25825444
- NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. | Fionda, C., et al. 2015. Biomed Res Int. 2015: 178698. PMID: 26161387
- DNAM-1 controls NK cell activation via an ITT-like motif. | Zhang, Z., et al. 2015. J Exp Med. 212: 2165-82. PMID: 26552706
- The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies. | Stein, N., et al. 2017. Hum Antibodies. 25: 111-119. PMID: 28035916
- Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis. | Alteber, Z., et al. 2021. Cancer Discov. 11: 1040-1051. PMID: 33687987
- DNAM-1 regulates Foxp3 expression in regulatory T cells by interfering with TIGIT under inflammatory conditions. | Sato, K., et al. 2021. Proc Natl Acad Sci U S A. 118: PMID: 34011606
- Renal cell carcinoma escapes NK cell-mediated immune surveillance through the downregulation of DNAM-1. | Tong, L., et al. 2023. Cancer Commun (Lond). 43: 855-859. PMID: 37314951
- DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy. | Cifaldi, L., et al. 2023. Front Immunol. 14: 1197053. PMID: 37359555
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DNAM-1 Antibody (11A8) | sc-53581 | 200 µg/ml | $316.00 | |||
DNAM-1 Antibody (11A8): m-IgG Fc BP-HRP Bundle | sc-538996 | 200 µg Ab; 10 µg BP | $354.00 | |||
DNAM-1 Antibody (11A8): m-IgG1 BP-HRP Bundle | sc-541197 | 200 µg Ab; 20 µg BP | $354.00 | |||
DNAM-1 Antibody (11A8) FITC | sc-53581 FITC | 200 µg/ml | $330.00 | |||
DNAM-1 Antibody (11A8) PE | sc-53581 PE | 200 µg/ml | $343.00 |